NL8403852A - Acylamino mitosanen; werkwijze voor het bereiden daarvan. - Google Patents

Acylamino mitosanen; werkwijze voor het bereiden daarvan. Download PDF

Info

Publication number: NL8403852A
Authority: NL; Netherlands
Prior art keywords: amino; methoxymitosane; compound; mitomycin; substituted
Prior art date: 1983-12-23

Application number

NL8403852A

Other languages

English (en)

Dutch (nl)

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-12-23

Filing date

1984-12-19

Publication date

1985-07-16

1984-12-19 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1985-07-16 Publication of NL8403852A publication Critical patent/NL8403852A/nl

Links

238000000034 method Methods 0.000 title claims description 8
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 116
150000001875 compounds Chemical class 0.000 claims description 68
229960004857 mitomycin Drugs 0.000 claims description 56
-1 2-chloroacetyl Chemical group 0.000 claims description 27
229910000104 sodium hydride Inorganic materials 0.000 claims description 20
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 11
239000000460 chlorine Substances 0.000 claims description 10
125000000129 anionic group Chemical group 0.000 claims description 8
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
125000006310 cycloalkyl amino group Chemical group 0.000 claims description 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
239000003495 polar organic solvent Substances 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000004414 alkyl thio group Chemical group 0.000 claims description 2
125000004659 aryl alkyl thio group Chemical group 0.000 claims description 2
125000005110 aryl thio group Chemical group 0.000 claims description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000001589 carboacyl group Chemical group 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
239000012312 sodium hydride Substances 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
125000003396 thiol group Chemical class [H]S* 0.000 claims 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
238000005481 NMR spectroscopy Methods 0.000 description 23
238000006243 chemical reaction Methods 0.000 description 22
238000012360 testing method Methods 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
241000699670 Mus sp. Species 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
230000000694 effects Effects 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
230000000259 anti-tumor effect Effects 0.000 description 8
230000008859 change Effects 0.000 description 8
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 6
239000004533 oil dispersion Substances 0.000 description 6
JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 6
JUJWROOIHBZHMG-QYKNYGDISA-N 2-deuteriopyridine Chemical compound [2H]C1=CC=CC=N1 JUJWROOIHBZHMG-QYKNYGDISA-N 0.000 description 5
229930192392 Mitomycin Natural products 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000007858 starting material Substances 0.000 description 5
208000001382 Experimental Melanoma Diseases 0.000 description 4
HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
235000019439 ethyl acetate Nutrition 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
238000000862 absorption spectrum Methods 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
150000008064 anhydrides Chemical group 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VHBFEIBMZHEWSX-UHFFFAOYSA-N 2-isothiocyanatopropane Chemical group CC(C)N=C=S VHBFEIBMZHEWSX-UHFFFAOYSA-N 0.000 description 2
LOLKAJARZKDJTD-UHFFFAOYSA-N 4-Ethoxy-4-oxobutanoic acid Chemical compound CCOC(=O)CCC(O)=O LOLKAJARZKDJTD-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
229910004298 SiO 2 Inorganic materials 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000005595 deprotonation Effects 0.000 description 2
238000010537 deprotonation reaction Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
230000003039 myelosuppressive effect Effects 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
150000003672 ureas Chemical class 0.000 description 2
JFOIBTLTZWOAIC-UHFFFAOYSA-N (4-nitrophenyl) 2,2,2-trifluoroacetate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)C(F)(F)F)C=C1 JFOIBTLTZWOAIC-UHFFFAOYSA-N 0.000 description 1
GMKZBFFLCONHDE-UHFFFAOYSA-N (4-nitrophenyl) benzoate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)C1=CC=CC=C1 GMKZBFFLCONHDE-UHFFFAOYSA-N 0.000 description 1
FFGGSHSHUKFELB-UHFFFAOYSA-N (4-nitrophenyl) methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 FFGGSHSHUKFELB-UHFFFAOYSA-N 0.000 description 1
NSBVDAMBDUXZAS-UHFFFAOYSA-N (4-nitrophenyl)methyl n-ethylcarbamate Chemical compound CCNC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 NSBVDAMBDUXZAS-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
RMQSINXLELHUAE-UHFFFAOYSA-N 1-[chloro(ethylsulfanyl)phosphoryl]oxyethane Chemical compound CCOP(Cl)(=O)SCC RMQSINXLELHUAE-UHFFFAOYSA-N 0.000 description 1
BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 1
JUJWROOIHBZHMG-RHQRLBAQSA-N 2,3,4,5-tetradeuteriopyridine Chemical compound [2H]C1=CN=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RHQRLBAQSA-N 0.000 description 1
AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 1
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
HNQRPLGPFCZIDQ-UHFFFAOYSA-N 3-benzyl-1-hydroxypyrrolidine-2,5-dione;carbonic acid Chemical compound OC(O)=O.O=C1N(O)C(=O)CC1CC1=CC=CC=C1 HNQRPLGPFCZIDQ-UHFFFAOYSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
UZUUQCBCWDBYCG-UHFFFAOYSA-N Mitomycin B Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(O)N2CC2C1N2C UZUUQCBCWDBYCG-UHFFFAOYSA-N 0.000 description 1
HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
125000000638 benzylaminocarbonyl group Chemical group C(C1=CC=CC=C1)NC(=O)* 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000001210 effect on neutrophils Effects 0.000 description 1
150000002168 ethanoic acid esters Chemical class 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000010439 graphite Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
238000009533 lab test Methods 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
VVWNENUJKRQDTB-UHFFFAOYSA-N o-ethyl methanethioate Chemical compound CCOC=S VVWNENUJKRQDTB-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000005677 organic carbonates Chemical class 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
AGUWUIVKDXDKBT-UHFFFAOYSA-N phenyl 2-chloroacetate Chemical compound ClCC(=O)OC1=CC=CC=C1 AGUWUIVKDXDKBT-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
HDGICZVUXOQTPV-UHFFFAOYSA-N phenylsulfanyl acetate Chemical compound CC(=O)OSC1=CC=CC=C1 HDGICZVUXOQTPV-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003566 thiocarboxylic acids Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL8403852A 1983-12-23 1984-12-19 Acylamino mitosanen; werkwijze voor het bereiden daarvan. NL8403852A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/564,806 US4642352A (en)	1983-12-23	1983-12-23	Acylamino mitosanes
US56480683		1983-12-23

Publications (1)

Publication Number	Publication Date
NL8403852A true NL8403852A (nl)	1985-07-16

Family

ID=24255968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8403852A NL8403852A (nl)	1983-12-23	1984-12-19	Acylamino mitosanen; werkwijze voor het bereiden daarvan.

Country Status (32)

Country	Link
US (1)	US4642352A (es)
JP (1)	JPS60169481A (es)
KR (1)	KR910009329B1 (es)
AR (1)	AR244231A1 (es)
AT (1)	AT386828B (es)
AU (1)	AU561376B2 (es)
BE (1)	BE901377A (es)
CA (1)	CA1239645A (es)
CH (1)	CH665641A5 (es)
DD (1)	DD228259A5 (es)
DE (1)	DE3447003C2 (es)
DK (1)	DK169477B1 (es)
ES (1)	ES538804A0 (es)
FI (1)	FI81099C (es)
FR (1)	FR2557112B1 (es)
GB (1)	GB2151627B (es)
GR (1)	GR82567B (es)
HU (1)	HU193245B (es)
IE (1)	IE57835B1 (es)
IL (1)	IL73876A (es)
IT (1)	IT1178792B (es)
LU (1)	LU85711A1 (es)
MY (1)	MY100976A (es)
NL (1)	NL8403852A (es)
NO (1)	NO163570C (es)
NZ (1)	NZ210254A (es)
OA (1)	OA07911A (es)
PT (1)	PT79741B (es)
SE (1)	SE8406577L (es)
SU (1)	SU1364239A3 (es)
YU (1)	YU45688B (es)
ZA (1)	ZA849907B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4487769A (en) *	1982-06-04	1984-12-11	Bristol-Myers Company	Amidines
NZ206932A (en) *	1983-02-07	1987-08-31	University Patents Inc	Certain 6-(heterocyclyl or amino) mitosanes and pharmaceutical compositions
US4803212A (en) *	1983-04-11	1989-02-07	Bristol-Myers Company	Amino disulfides
FR2571373A1 (fr) *	1984-10-09	1986-04-11	Bristol Myers Co	Procede de preparation de derives n7-substitues de la mitomycine c
CA1282069C (en) *	1985-09-12	1991-03-26	Damon L. Meyer	Antibody complexes of hapten-modified diagnostic or therapeutic agents
JPS6354380A (ja) *	1986-08-26	1988-03-08	Kyowa Hakko Kogyo Co Ltd	マイトマイシン誘導体
ZA886812B (en) *	1987-11-23	1989-07-26	Bristol Myers Co	Anti-tumor prodrugs
US4874779A (en) *	1988-06-29	1989-10-17	Bristol-Myers Company	Mitomycin phosphate derivatives
US5214804A (en) *	1992-01-27	1993-06-01	Carey Michael J	Protective mask with scarf

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US27384A (en) *		1860-03-06		Slide-valve for steam-engines
BE655399A (es) *
CA771155A (en) *		1967-11-07	Matsui Masanao	Phosphorus-containing derivatives of mitomycin c
US3660578A (en) *	1957-04-06	1972-05-02	Kyowa Hakko Kogyo Kk	Mitomycin c
NL129868C (es) *	1963-06-07
DE1570029A1 (de) *	1964-07-09	1970-04-09	Kyowa Hakko Kogyo Kk	Verfahren zur Herstellung von Mitosanverbindungen
US3420846A (en) *	1964-08-25	1969-01-07	Kyowa Hakko Kogyo Kk	7-substituted mitomycin a
US3332944A (en) *	1964-11-02	1967-07-25	American Cyanamid Co	Antibiotic derivatives of mitomycins a, b, c and porfiromycin
FR1540921A (fr) *	1965-05-18	1968-10-04	Kyowa Hakko Kogyo Kk	Procédé de préparation de dérivés de thio-urée de la mitomycine c
US3410867A (en) *	1965-11-22	1968-11-12	Kyowa Hakko Kogyo Kk	Mitomycin derivatives
JPS5439098A (en) *	1977-08-31	1979-03-24	Kyowa Hakko Kogyo Co Ltd	Mitomycin c derivatives
EP0008021B1 (en) *	1978-07-18	1984-05-16	Kyowa Hakko Kogyo Co., Ltd	New mitomycins and processes for production thereof
US4268676A (en) *	1979-12-05	1981-05-19	University Patents, Inc.	Mitomycin analogs
US4444768A (en) *	1980-03-04	1984-04-24	Ciba-Geigy Corporation	Pyrimido[1,6-a]indoles, pharmaceutical preparations containing them, and methods of treating pain and inflammation with them
NZ199617A (en) *	1981-05-15	1985-08-30	University Patents Inc	Azirino(2',3',:3,4)pyrrolo(1,2-a)indole-4,7-dione derivatives and pharmaceutical compositions
JPS58201791A (ja)	1982-05-19	1983-11-24	Katsuo Unno	ヘマトポルフイリン誘導体
US4487769A (en) *	1982-06-04	1984-12-11	Bristol-Myers Company	Amidines

1983
- 1983-12-23 US US06/564,806 patent/US4642352A/en not_active Expired - Fee Related
1984
- 1984-11-20 AU AU35710/84A patent/AU561376B2/en not_active Ceased
- 1984-11-20 NZ NZ210254A patent/NZ210254A/en unknown
- 1984-12-06 AR AR84298866A patent/AR244231A1/es active
- 1984-12-11 FR FR8418904A patent/FR2557112B1/fr not_active Expired
- 1984-12-12 CA CA000469874A patent/CA1239645A/en not_active Expired
- 1984-12-19 NO NO845100A patent/NO163570C/no unknown
- 1984-12-19 FI FI845037A patent/FI81099C/fi not_active IP Right Cessation
- 1984-12-19 ZA ZA849907A patent/ZA849907B/xx unknown
- 1984-12-19 YU YU215284A patent/YU45688B/sh unknown
- 1984-12-19 NL NL8403852A patent/NL8403852A/nl not_active Application Discontinuation
- 1984-12-19 ES ES538804A patent/ES538804A0/es active Granted
- 1984-12-20 CH CH6091/84A patent/CH665641A5/de not_active IP Right Cessation
- 1984-12-20 IL IL73876A patent/IL73876A/xx not_active IP Right Cessation
- 1984-12-21 BE BE0/214237A patent/BE901377A/fr not_active IP Right Cessation
- 1984-12-21 LU LU85711A patent/LU85711A1/fr unknown
- 1984-12-21 AT AT0407484A patent/AT386828B/de not_active IP Right Cessation
- 1984-12-21 OA OA58488A patent/OA07911A/xx unknown
- 1984-12-21 IE IE3318/84A patent/IE57835B1/en not_active IP Right Cessation
- 1984-12-21 DD DD84271473A patent/DD228259A5/de not_active IP Right Cessation
- 1984-12-21 DE DE3447003A patent/DE3447003C2/de not_active Expired - Fee Related
- 1984-12-21 JP JP59268757A patent/JPS60169481A/ja active Granted
- 1984-12-21 HU HU844801A patent/HU193245B/hu not_active IP Right Cessation
- 1984-12-21 PT PT79741A patent/PT79741B/pt not_active IP Right Cessation
- 1984-12-21 SE SE8406577A patent/SE8406577L/xx unknown
- 1984-12-21 GB GB08432513A patent/GB2151627B/en not_active Expired
- 1984-12-21 SU SU843826167A patent/SU1364239A3/ru active
- 1984-12-21 DK DK621484A patent/DK169477B1/da active
- 1984-12-21 GR GR82567A patent/GR82567B/el unknown
- 1984-12-21 IT IT24227/84A patent/IT1178792B/it active
- 1984-12-22 KR KR1019840008275A patent/KR910009329B1/ko not_active IP Right Cessation
1987
- 1987-09-29 MY MYPI87002232A patent/MY100976A/en unknown

Also Published As

Publication number	Publication date
ATA407484A (de)	1988-03-15
FR2557112A1 (fr)	1985-06-28
YU215284A (en)	1990-06-30
IT8424227A0 (it)	1984-12-21
FR2557112B1 (fr)	1987-02-13
SE8406577L (sv)	1985-06-24
IL73876A (en)	1991-08-16
JPH0471076B2 (es)	1992-11-12
ZA849907B (en)	1985-08-28
DD228259A5 (de)	1985-10-09
FI81099C (fi)	1990-09-10
HU193245B (en)	1987-08-28
AU561376B2 (en)	1987-05-07
KR910009329B1 (ko)	1991-11-11
NO163570B (no)	1990-03-12
MY100976A (en)	1991-06-15
AU3571084A (en)	1985-06-27
LU85711A1 (fr)	1985-09-12
FI81099B (fi)	1990-05-31
GB8432513D0 (en)	1985-02-06
OA07911A (fr)	1986-11-20
FI845037A0 (fi)	1984-12-19
DK621484A (da)	1985-06-24
CA1239645A (en)	1988-07-26
DK621484D0 (da)	1984-12-21
NO163570C (no)	1990-06-20
IE57835B1 (en)	1993-04-21
SU1364239A3 (ru)	1987-12-30
GB2151627B (en)	1988-03-30
GR82567B (en)	1985-04-23
GB2151627A (en)	1985-07-24
PT79741A (en)	1985-01-01
DE3447003C2 (de)	1994-11-17
HUT37434A (en)	1985-12-28
AR244231A1 (es)	1993-10-29
ES8603485A1 (es)	1985-12-16
KR850004762A (ko)	1985-07-27
FI845037L (fi)	1985-06-24
PT79741B (en)	1987-01-16
SE8406577D0 (sv)	1984-12-21
IL73876A0 (en)	1985-03-31
DK169477B1 (da)	1994-11-07
BE901377A (fr)	1985-06-21
JPS60169481A (ja)	1985-09-02
YU45688B (sh)	1992-07-20
NO845100L (no)	1985-06-24
IE843318L (en)	1985-06-23
ES538804A0 (es)	1985-12-16
IT1178792B (it)	1987-09-16
AT386828B (de)	1988-10-25
DE3447003A1 (de)	1985-07-04
NZ210254A (en)	1988-02-29
US4642352A (en)	1987-02-10
CH665641A5 (de)	1988-05-31

Legal Events

Date	Code	Title	Description
1990-05-16	DNT	Communications of changes of names of applicants whose applications have been laid open to public inspection	Free format text: BRISTOL-MYERS SQUIBB COMPANY
1992-01-02	BA	A request for search or an international-type search has been filed
1992-02-03	BB	A search report has been drawn up
1992-03-02	BC	A request for examination has been filed
1996-06-03	BV	The patent application has lapsed

Publication	Publication Date	Title
CN110546151B (zh)	2023-04-28	凋亡诱导剂
AU744986B2 (en)	2002-03-07	Cyclin dependent kinase inhibiting purine derivatives
NL8001531A (nl)	1981-01-20	Nieuwe benzodiazepineverbindingen.
CA1276635C (en)	1990-11-20	9-(2-(hydroxymethyl)cycloalkylmethyl)guanines
EA005950B1 (ru)	2005-08-25	Производные бензимидазола, их получение и терапевтическое применение
US4675404A (en)	1987-06-23	8-pyridazinylcarbamoyl ergolines
CA1230333A (en)	1987-12-15	Amidine derivatives of mitomycin a, mitomycin c and porfiromycin having antitumor activity and processes for their production
NL8403852A (nl)	1985-07-16	Acylamino mitosanen; werkwijze voor het bereiden daarvan.
CN110139857B (zh)	2023-07-21	作为吲哚胺2,3-双加氧酶抑制剂的亚砜亚胺、磺酰亚胺酰胺、磺酰二亚胺和二酰亚胺磺酰胺化合物
EP0256137B1 (en)	1992-12-23	Bis-dioxopiperazine derivatives
US4803212A (en)	1989-02-07	Amino disulfides
US4835160A (en)	1989-05-30	Derivatives of pyridoindole, having anti-tumor properties
HU200461B (en)	1990-06-28	Process for producing new 9-(n-hyudroxyalkoxy)-purine derivatives and pharmaceutical compositions comprising such compounds
EP0631583A1 (en)	1995-01-04	Antiviral phosphonic acid derivatives of purine analogues
US4849423A (en)	1989-07-18	Purine derivatives, medicaments containing them and methods of treating cardiac insufficiencies and irregularities with them.
EP0390181B1 (en)	1995-05-10	Perylenequinone (UCN-1028D) derivatives
US4691023A (en)	1987-09-01	Amino disulfides
US3238207A (en)	1966-03-01	6-oxyorganopurines and method of preparing them
US4652644A (en)	1987-03-24	Process for preparation of N7 -amidino substituted mitomycin C derivatives
US5252569A (en)	1993-10-12	6-substituted purinyl piperazine derivatives
US5099016A (en)	1992-03-24	Substituted 7-oxomitosanes
JPH0586791B2 (es)	1993-12-14
TAKAMIZAWA et al.	1974	Studies on Pyrimidine Derivatives and Their Related Compounds. LXXXVI. Unusual Reactions of Thiamine Derivatives
GB2090254A (en)	1982-07-07	Oxazolidinedione sulfide compounds
KR20000051515A (ko)	2000-08-16	항바이러스 활성을 가지는 2-아미노퓨린